J1 MAC: Prostate Molecular Markers Not Covered
- By admin aapc
- In Billing
- June 18, 2012
- No Comments
Billing and coding guidelines for prostate molecular marker claims submitted to Palmetto GBA have changed. The Part B Medicare administrative contractor (MAC) for jurisdiction 1 (American Samoa, California, Guam, Hawaii, Nevada, and Northern Mariana Islands) has determined the service to be medically unnecessary and will not reimburse physicians for HOXD3, PTEN, and ERG molecular markers.
Among other considerations, patients should be informed that molecular markers are not covered under Medicare, and an Advanced Beneficiary Notice (ABN) for the service should be retained on file.
Complete instructions for how to submit a claim to receive a service denial were posted June 1 on Palmetto’s website.
Latest posts by admin aapc (see all)
- Message From Your Region 6 Representatives | Pam Tienter and Jean Pryor - November 15, 2019
- October | Breast Cancer Awareness Month - September 20, 2019
- US gets the ball rolling on ICD-11 - August 16, 2019
Leave a Reply